168 related articles for article (PubMed ID: 1489900)
21. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
22. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.
Lau CS; McLaren M; Hanslip J; Kerr M; Belch JJ
Ann Rheum Dis; 1993 Sep; 52(9):643-9. PubMed ID: 8239758
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Choudhury NA; Pietraszek MH; Hachiya T; Baba S; Sakaguchi S; Takada Y; Takada A
Thromb Res; 1992 May; 66(4):321-9. PubMed ID: 1412199
[TBL] [Abstract][Full Text] [Related]
24. A study of the fibrinolytic response in healthy men and women following a brief exposure to venous occlusion.
Lacroix KA; Bean C; Box L; Wagner K
Thromb Res; 1996 Jan; 81(1):133-43. PubMed ID: 8747528
[TBL] [Abstract][Full Text] [Related]
25. Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
Li Y; Chen H; Tan J; Wang X; Liang H; Sun X
Eur J Clin Invest; 1998 Dec; 28(12):1050-4. PubMed ID: 9893018
[TBL] [Abstract][Full Text] [Related]
26. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis.
Comerota AJ; Chouhan V; Harada RN; Sun L; Hosking J; Veermansunemi R; Comerota AJ; Schlappy D; Rao AK
Ann Surg; 1997 Sep; 226(3):306-13; discussion 313-4. PubMed ID: 9339937
[TBL] [Abstract][Full Text] [Related]
27. Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Mehta P; Parker RI
J Pediatr Hematol Oncol; 2010 Oct; 32(7):532-6. PubMed ID: 20686427
[TBL] [Abstract][Full Text] [Related]
28. Fibrinolytic and inflammatory processes in pleural effusions.
Philip-Joët F; Alessi MC; Philip-Joët C; Aillaud M; Barriere JR; Arnaud A; Juhan-Vague I
Eur Respir J; 1995 Aug; 8(8):1352-6. PubMed ID: 7489803
[TBL] [Abstract][Full Text] [Related]
29. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
[TBL] [Abstract][Full Text] [Related]
30. The release of plasminogen activators (t-PA and u-PA) and plasminogen activator inhibitor (PAI-1) after venous stasis.
Falkon L; Garí M; Borrell M; Fontcuberta J
Blood Coagul Fibrinolysis; 1992 Feb; 3(1):33-8. PubMed ID: 1623118
[TBL] [Abstract][Full Text] [Related]
31. Response of fibrinolytic proteins and endothelin 1 to venous occlusion in patients on chronic hemodialysis.
Tomura S; Ando R; Chida Y; Ida T; Hirata Y; Marumo F; Tsuchiya S
Nephron; 1997; 77(4):394-8. PubMed ID: 9434059
[TBL] [Abstract][Full Text] [Related]
32. The effects of green pit viper (Trimeresurus albolabris and Trimeresurus macrops) venom on the fibrinolytic system in human.
Rojnuckarin P; Intragumtornchai T; Sattapiboon R; Muanpasitporn C; Pakmanee N; Khow O; Swasdikul D
Toxicon; 1999 May; 37(5):743-55. PubMed ID: 10219986
[TBL] [Abstract][Full Text] [Related]
33. Correlation between changes induced by venous occlusion on factor VIII-von Willebrand factor components and fibrinolytic activity.
Ponari O; Pini M; Poli T; Poti R; Dettori AG
Haemostasis; 1984; 14(2):179-83. PubMed ID: 6429015
[TBL] [Abstract][Full Text] [Related]
34. [Impaired fibrinolytic response to the venous occlusion test in patients with cryptogenic colitis].
Gris JC; Schved JF; Raffanel C; Dubois A; Ribard D; Balmes JL
Gastroenterol Clin Biol; 1991; 15(12):933-8. PubMed ID: 1783249
[TBL] [Abstract][Full Text] [Related]
35. The coagulation/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome.
Ames PR; Lupoli S; Alves J; Atsumi T; Edwards C; Iannaccone L; Khamashta MA; Hughes GR; Brancaccio V
Br J Rheumatol; 1997 Oct; 36(10):1045-50. PubMed ID: 9374919
[TBL] [Abstract][Full Text] [Related]
36. Abnormal fibrinolysis in healthy male cigarette smokers: role of plasminogen activator inhibitors.
Haire WD; Goldsmith JC; Rasmussen J
Am J Hematol; 1989 May; 31(1):36-40. PubMed ID: 2495714
[TBL] [Abstract][Full Text] [Related]
37. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation.
Sartori TM; Maurizio PG; Sara P; Ugolino L; Annalisa A; Panagiotis T; Massimo F; Antonio G
J Heart Lung Transplant; 1999 Jul; 18(7):693-700. PubMed ID: 10452346
[TBL] [Abstract][Full Text] [Related]
38. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus.
Takada Y; Urano T; Watanabe I; Taminato A; Yoshimi T; Takada A
Thromb Res; 1993 Sep; 71(5):405-15. PubMed ID: 8236167
[TBL] [Abstract][Full Text] [Related]
39. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion.
Cugno M; Uziel L; Fabrizi I; Bottasso B; Maggiolini F; Agostoni A
Thromb Res; 1989 Dec; 56(5):625-34. PubMed ID: 2516662
[TBL] [Abstract][Full Text] [Related]
40. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
